OBJECTIVE： To provide reference for rational use of recombinant human granulocyte-colony stimulating factor （rhG-CSF） in cancer patients. METHODS： Referring to the expert advice and guideline of clinical application of rhG-CSF at home and abroad， DUE criteria on rhG-CSF for cancer patients was established； questionnaire was designed， and the medical records of rhG-CSF in a third grade class A hospital was evaluated. RESULTS： The DUE criterion on rhG-CSF for cancer patients included 3 parts， such as drug indications， the course of medication and medication results， 14 items in total. Through the implementation of DUE， retrospective evaluation of 220 medical records showed that the application of rhG-CSF was up to the standard in respects of drug indications， no contraindication， routine blood test and drug interaction monitoring at least twice every week， there still was irrational phenomenon. CONCLUSIONS： The established DUE criterion on rhG-CSF for cancer patients is with the characteristics of definite content， target and paracticabilitg， which can provide reference for the work development of clinical pharmacists.